Black Diamond Therapeutics, Inc.
$3.05
▲
2.58%
2026-04-21 05:36:01
www.blackdiamondtherapeutics.com
NMS: BDTX
Explore Black Diamond Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$175.3 M
Current Price
$3.05
52W High / Low
$4.94 / $1.31
Stock P/E
7.84
Book Value
$1.96
Dividend Yield
—
ROCE
15.61%
ROE
22.88%
Face Value
—
EPS
$0.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
3.39
Debt / Equity
16.74
Current Ratio
8.42
Quick Ratio
8.42
Forward P/E
-2.48
Price / Sales
2.1
Enterprise Value
$36.79 M
EV / EBITDA
1.82
EV / Revenue
0.53
Rating
None
Target Price
$9.71
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 2. | Xenetic Biosciences, Inc. | $3.4 | — | $7.09 M | — | -38.33% | -40% | $13.93 / $1.9 | $3.23 |
| 3. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 4. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 5. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 6. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 7. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 70 M | 0 M |
| Operating Profit | -10.26 M | -10.98 M | -13.42 M | 54.53 M | -18.27 M |
| Net Profit | -15.12 M | -8.5 M | -10.56 M | 56.54 M | -15.98 M |
| EPS in Rs | -0.26 | -0.15 | -0.18 | 0.99 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 70 M | 0 M | 0 M | 0 M |
| Operating Profit | 19.87 M | -78.78 M | -86.46 M | -92.83 M |
| Net Profit | 22.37 M | -69.68 M | -82.44 M | -91.17 M |
| EPS in Rs | 0.39 | -1.22 | -1.44 | -1.59 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 143.01 M | 122.64 M | 158.57 M | 156.25 M |
| Total Liabilities | 30.8 M | 39.35 M | 41.83 M | 40.56 M |
| Equity | 112.21 M | 83.28 M | 116.74 M | 115.69 M |
| Current Assets | 132.44 M | 101.18 M | 134.03 M | 127.71 M |
| Current Liabilities | 15.73 M | 20.57 M | 19.65 M | 15.26 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 29.61 M | -62.3 M | -66.72 M | -85.08 M |
| Investing CF | -44.91 M | 16.97 M | 16.35 M | 53.37 M |
| Financing CF | -0.15 M | 25.55 M | 71.93 M | 0.18 M |
| Free CF | 29.61 M | -62.3 M | -66.75 M | -85.27 M |
| Capex | — | — | -0.03 M | -0.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 15.48% | 9.57% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.